Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEXAVAC upgraded process versus current process in healthy infants
2005-002578-31Phase 3Terminated
- Sponsor
- Sanofi Pasteur MSD S.N.C.
- Start
- Jul 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Hexavac in diphtheria, Tetanus, pertussis and 3 more (2 arms), sponsored by Sanofi Pasteur MSD S.N.C. Primary endpoints: Anti-HBs seroprotection rate after primary series or booster and Safety. Started Jul 2005; status: terminated.
02
Drugs
Hexavac
03
Conditions
diphtheriaTetanuspertussishepatitis B (HBV)poliomyelitis
Beyond the preview
Go deeper on 2005-002578-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002578-31.